訊飛醫療2024年業績亮眼,B端業務加速增長103%
據港交所公告,訊飛醫療(2506.HK)於3月26日發佈2024年全年業績報告。公司全年實現營收7.34億元,同比增長32.0%;毛利達4.04億元,同比增長28.4%,毛利率保持在55.1%。其中,B端業務表現亮眼,收入由2023年的6491萬元增至1.32億元,同比增長103%,成爲公司增長新引擎。患者服務收入同比增長56.6%,區域管理平臺解決方案增長31.8%。公司收入結構持續優化,B端和C端業務佔總收入比例從2023年的26%提升至2024年的47%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.